🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery

Recruitingn/aAges 18 Years - 90 YearsAllImperial College London
NCT06289374 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in England and Wales with 16,000 new cases diagnosed every year. Survival rates are poor with only 15% surviving beyond 5 years. There is also increasing research to understand the cancer biology and factors allowing cancers to progress. It is likely there is a relationship between the cancer-specific microbiome, cells related to inflammation, which promotes cancer progression. The BIORESOURCE 1 study has established a comprehensive resource of matched samples from patients with oesophageal and gastric cancer. This longitudinal study aims to obtain further matched biosamples in the follow-up period after cancer surgery to find biomarkers that may predict treatment response, recurrence and/or long term prognosis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Aged 18-90 years at the time of initial recruitment * Gastric/oesophageal adenocarcinoma cohort (biopsy proven adenocarcinoma) recruited into BIORESOURCE 1 Exclusion Criteria: * Oesophageal squamous cell carcinoma * Previous oesophageal and gastric resection * History of another cancer within five years. If a new other cancer type is diagnosed within the sampling time frame, no further samples will be taken. * Participants with co-morbidities preventing breath collection * Unable or unwilling to provide informed written consent * Pregnant women
💊

What it tests

  • Biosample collection
📍

Where

1 site
Imperial College Healthcare NHS Trust
London, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy